Bristol-Myers Squibb Co vs Ford Motor Company — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Ford Motor Company trades at $13.84 (market cap $55.75B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.3× Ford Motor Company's market cap, and Ford Motor Company pays the higher dividend (4.29%). Which is the better fit depends on your goals.
| BMY | F | |
|---|---|---|
Market Cap | $129.94B | $55.75B |
Sector | Health | Consumer Cyclical |
52-Week High | $65.89 | $17.44 |
52-Week Low | $42.60 | $11.21 |
Enterprise Value | $163.92B | $187.71B |
Dividend Yield | 3.96% | 4.29% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
Ford Motor Company (F) trades at $13.865, down 1.07% on the day, with a bearish technical signal. Recent earnings show volatility, with Q2 2026 beating expectations but Q4 2025 missing. The company reported a net loss of $8.18B in 2025 despite $187.27B revenue, though operating cash flow remains strong at $21.28B. News highlights the upcoming Fathom EV truck priced at $28,350, targeting affordability in 2027.
The outlook is mixed; low P/E of 11.84 and analyst consensus price target of $16.18 suggest potential upside, but negative net income margin and high debt pose risks. Investor sentiment is cautious amid EV transition costs and competitive pressures, with 38.3% of analysts rating Buy. Key opportunities include new affordable models and strong cash flow, while execution on profitability remains critical.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →